NO20082482L - Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer - Google Patents

Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer

Info

Publication number
NO20082482L
NO20082482L NO20082482A NO20082482A NO20082482L NO 20082482 L NO20082482 L NO 20082482L NO 20082482 A NO20082482 A NO 20082482A NO 20082482 A NO20082482 A NO 20082482A NO 20082482 L NO20082482 L NO 20082482L
Authority
NO
Norway
Prior art keywords
kinase inhibitors
carbonylamino
pyrazoles
pyrrole
well
Prior art date
Application number
NO20082482A
Other languages
English (en)
Inventor
Jayashree Girish Tikhe
Indrawan James Mcalpine
Haitao Li
Anle Yang
Junhu Zhang
Liming Dong
Chuangxing Guo
Yufeng Hong
Mary Catherine Johnson
Susan Elizabeth Kephart
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20082482L publication Critical patent/NO20082482L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det beskrives karbonylaminopyrrolpyrazolforbindelser av formel (1), sammensetninger inneholdende disse forbindelser, og fremgangsmåter for anvendelse av samme. Foretrukne forbindelser av formel (1) har aktivitet som protein kinaseinhibitorer, inkludert som inhibitorer av PAK4..
NO20082482A 2005-12-21 2008-06-02 Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer NO20082482L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75334905P 2005-12-21 2005-12-21
US86493206P 2006-11-08 2006-11-08
PCT/IB2006/003646 WO2007072153A2 (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20082482L true NO20082482L (no) 2008-07-02

Family

ID=38189022

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082482A NO20082482L (no) 2005-12-21 2008-06-02 Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer

Country Status (27)

Country Link
US (1) US7884117B2 (no)
EP (1) EP1979356B1 (no)
JP (1) JP4635089B2 (no)
KR (1) KR101029167B1 (no)
AP (1) AP2369A (no)
AU (1) AU2006327866B2 (no)
BR (1) BRPI0620354A2 (no)
CA (1) CA2634381C (no)
CR (1) CR10094A (no)
CU (1) CU23751B7 (no)
DK (1) DK1979356T3 (no)
EA (1) EA015513B1 (no)
EC (1) ECSP088558A (no)
ES (1) ES2435405T3 (no)
GE (1) GEP20104974B (no)
HK (1) HK1128290A1 (no)
HR (1) HRP20130976T1 (no)
IL (1) IL191776A (no)
MA (1) MA30076B1 (no)
ME (1) MEP0808A (no)
MY (1) MY151455A (no)
NO (1) NO20082482L (no)
NZ (1) NZ568692A (no)
PL (1) PL1979356T3 (no)
PT (1) PT1979356E (no)
RS (2) RS20080281A (no)
WO (1) WO2007072153A2 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
AU2010270714B2 (en) 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US10428019B2 (en) * 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
WO2012065935A1 (en) 2010-11-17 2012-05-24 F. Hoffmann-La Roche Ag Methods of treating tumors
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
DK2734208T3 (en) 2011-07-19 2017-06-19 Wave Life Sciences Ltd PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
RU2014141018A (ru) 2012-03-16 2016-05-10 Ф. Хоффманн-Ля Рош Аг Способы лечения меланомы ингибиторами рак1
SG11201500232UA (en) 2012-07-13 2015-04-29 Wave Life Sciences Pte Ltd Chiral control
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10160969B2 (en) 2014-01-16 2018-12-25 Wave Life Sciences Ltd. Chiral design
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10131679B2 (en) 2014-10-31 2018-11-20 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole compound
CA2972239A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2989519C (en) 2015-06-15 2023-09-26 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
US20220002303A1 (en) 2018-11-14 2022-01-06 Ube Industries, Ltd. Dihydropyrrolopyrazole derivative
US20220089611A1 (en) * 2018-12-28 2022-03-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2020212484A1 (en) 2019-04-17 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001287654B2 (en) 2000-08-10 2006-12-14 Pfizer Italia S.R.I. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP2005537290A (ja) 2002-07-25 2005-12-08 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物
GB0229526D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
UA81790C2 (uk) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
EP1838718B1 (en) 2005-01-10 2011-06-15 Pfizer Inc. Pyrrolopyrazoles, potent kinase inhibitors

Also Published As

Publication number Publication date
IL191776A0 (en) 2008-12-29
EA015513B1 (ru) 2011-08-30
EP1979356B1 (en) 2013-09-18
CU23751B7 (es) 2012-01-31
ES2435405T3 (es) 2013-12-19
CA2634381C (en) 2011-03-08
HRP20130976T1 (hr) 2013-11-22
EA200801291A1 (ru) 2008-12-30
CU20080115A7 (es) 2010-08-30
RS53029B (en) 2014-04-30
GEP20104974B (en) 2010-04-26
AP2008004506A0 (en) 2008-06-30
NZ568692A (en) 2011-07-29
PT1979356E (pt) 2013-11-21
US20090318440A1 (en) 2009-12-24
DK1979356T3 (da) 2013-11-18
KR20080080567A (ko) 2008-09-04
WO2007072153A8 (en) 2008-08-14
IL191776A (en) 2013-03-24
MY151455A (en) 2014-05-30
PL1979356T3 (pl) 2014-01-31
ME00006B (me) 2010-02-10
CA2634381A1 (en) 2007-06-28
AU2006327866B2 (en) 2012-06-14
KR101029167B1 (ko) 2011-04-12
AP2369A (en) 2012-02-29
BRPI0620354A2 (pt) 2011-11-08
US7884117B2 (en) 2011-02-08
ECSP088558A (es) 2008-07-30
MA30076B1 (fr) 2008-12-01
AU2006327866A1 (en) 2007-06-28
JP4635089B2 (ja) 2011-02-16
RS20080281A (en) 2009-09-08
MEP0808A (xx) 2010-02-10
WO2007072153A2 (en) 2007-06-28
HK1128290A1 (en) 2009-10-23
WO2007072153A3 (en) 2007-10-25
CR10094A (es) 2008-08-01
EP1979356A2 (en) 2008-10-15
JP2009520805A (ja) 2009-05-28

Similar Documents

Publication Publication Date Title
NO20082482L (no) Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer
CY1111752T1 (el) Πυρρολοπυραζολες, δυναμικοι αναστολεις κινασης
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
WO2007079164A3 (en) Protein kinase inhibitors
NO20070526L (no) Kinazolindionderivater som parp-inhibitorer
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
ATE479687T1 (de) Kinaseinhibitoren
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
WO2006050109A3 (en) Novel kinase inhibitors
ATE433447T1 (de) Pyrimiidinverbindungen
NO20072058L (no) Inhibitorer av interaksjonen mellom MDM2 og P53
MX2008001538A (es) Aril piridinas y metodos para su uso.
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
NO20050828L (no) lndol-3-svovelderivater
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
NO20082256L (no) Pyrazolderivater, preparater som inneholder slike forbindelser, og fremgangsmåter for anvendelse
EA201270630A1 (ru) Гетероциклические сетр ингибиторы
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application